Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity

Structure

Volumn 12, Issue 10, 2004, Pages 1799-1807

  Barrientos, Laura G ^a,b   Lasala, Fátima ^c   Delgado, Rafael ^c   Sanchez, Anthony ^b   Gronenborn, Angela M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOVIRIN N; DIMER; MONOMER;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; EBOLA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN STABILITY; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BACTERIAL PROTEINS; BIOLOGICAL ASSAY; CARRIER PROTEINS; DIMERIZATION; EBOLAVIRUS; HIV-1; MUTATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS;

EBOLA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 4644253146     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2004.07.019     Document Type: Article

References (22)

1. Barrientos L.G., Gronenborn A.M. The domain-swapped dimer of cyanovirin-N contains two sets of oligosaccharide binding sites in solution. Biochem. Biophys. Res. Commun. 298:2002;598-602
2. Barrientos L.G., Gronenborn A.M. The highly-specific carbohydrate binding protein Cyanovirin-N. structure, anti-HIV/Ebola activity and possibilities for therapy Mini Rev. Med. Chem. in press:2004
3. Barrientos L.G., Louis J.M., Botos I., Mori T., Han Z., O'Keefe B.R., Boyd M.R., Wlodawer A., Gronenborn A.M. The domain-swapped dimer of cyanovirin-N is in a metastable folded state. reconciliation of X-ray and NMR structures Structure. 10:2002;673-686
4. 1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 58:2003;47-56
5. Barrientos L.G., Lasala F., Otero J.R., Sanchez A., Delgado R. In vitro evaluation of Cyanovirin-N antiviral activity, by use of Lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J. Infect. Dis. 189:2004;1440-1443
6. Bewley C.A., Gustafson K.R., Boyd M.R., Covell D.G., Bax A., Clore G.M., Gronenborn A.M. Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat. Struct. Biol. 5:1998;571-578
7. Botos I., O'Keefe B.R., Shenoy S.R., Cartner L.K., Ratner D.M., Seeberger P.H., Boyd M.R., Wlodawer A. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J. Biol. Chem. 277:2002;34336-34342. a
8. Botos I., Mori T., Cartner L.K., Boyd M.R., Wlodawer A. Domain-swapped structure of a mutant of cyanovirin-N. Biochem. Biophys. Res. Commun. 294:2002;184-190. b
9. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120. potential applications to microbicide development Antimicrob. Agents Chemother. 41:1997;1521-1530
10. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe. a multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR. 6:1995;277-293
11. Han Z., Xiong C., Mori T., Boyd M.R. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library. Biochem. Biophys. Res. Commun. 292:2002;1036-1043
12. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:1995;6705-6711
13. Kelley B.S., Chang L.C., Bewley C.A. Engineering an obligate domain-swapped dimer of cyanovirin-N with enhanced anti-HIV activity. J. Am. Chem. Soc. 124:2002;3210-3211
14. Kuhlman B., O'Neill J.W., Kim D.E., Zhang K.Y.J., Baker D. Conversion of monomeric protein L to an obligate dimer by computational protein design. Proc. Natl. Acad. Sci. USA. 98:2001;10687-10691
15. Mori T., Gustafson K.R., Pannell L.K., Shoemaker R.H., Wu L., McMahon J.B., Boyd M.R. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr. Purif. 12:1998;151-158
16. Mori T., Barrientos L.G., Han Z., Gronenborn A.M., Turpin J.A., Boyd M.R. Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. Protein Expr. Purif. 26:2002;42-49
17. O'Keefe B.R., Smee D.F., Turpin J.A., Turpin J.A., Saucedo C.J., Gustafson K.R., Mori T., Blakeslee D., Buckheit R., Boyd M.R. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47:2003;2518-2525
18. Sanchez A., Yang Z.Y., Xu L., Nabel G.J., Crews T., Peters C.J. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72:1998;6442-6447
19. Shenoy S.R., Barrientos L.G., Ratner D.M., O'Keefe B.R., Seeberger P.H., Gronenborn A.M., Boyd M.R. Multisite and multivalent binding between Cyanovirin-N and branched oligomannosides. calorimetric and NMR characterization Chem. Biol. 9:2002;1109-1118
20. Yang F., Bewley C.A., Louis J.M., Gustafson K.R., Boyd M.R., Gronenborn A.M., Clore G.M., Wlodawer A. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J. Mol. Biol. 288:1999;403-412. a
21. Yang S., Delgado R., King S.R., Woffendin C., Barker C.S., Yang Z.Y., Zu L., Nolan G.P., Nabel G.J. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10:1999;123-132. b
22. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kaapes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:2002;1896-1905